VISTA, Calif., and SAN ANTONIO, July 13 /PRNewswire/ -- Nexa Orthopedics, Inc., (“Nexa”) and OsteoBiologics, Inc. (“OBI”) announced today the execution of a private label distribution agreement, whereby Nexa will have the exclusive right to distribute certain OBI products designed for use in hand and foot and ankle surgery in the United States under Nexa’s OsteoCure(TM) biologic products brand. The companies also agreed to pursue various partnership expansion opportunities, including the collaborative development of new products using proprietary OBI technology for reconstructive surgery of the extremities.
“A focused distribution channel, key thought leader relationships and deep management experience in the category [all] position Nexa as an ideal partner for OBI in the extremities sub-specialties,” said Fred Dinger, OBI President and CEO. Paul Nichols, Nexa President and CEO commented, “We believe OBI’s PolyGraft(TM) biomaterials technology offers unique value for extremities applications with the potential for significantly improving clinical practice and patient outcomes.” Nexa will introduce the OsteoCure products July 14, 2005 at the American Orthopedic Foot and Ankle Society 21st Annual Summer Meeting in Boston.
About Nexa Orthopedics, Inc.
Nexa Orthopedics, Inc. was founded in 2004 by HealthpointCapital to create the pre-eminent company in extremities surgery through a program of business investments, technology in-licensing and internal development. Paul Nichols, Nexa President and CEO, has 15 years experience in extremities orthopedics as both an executive and entrepreneur, including founding Avanta Orthopaedics Corporation. Nexa recently acquired Futura Biomedical LLC, a market leader in forefoot arthroplasty and arthroereisis.
About OsteoBiologics, Inc.
OBI, located in San Antonio, Texas, is a private company that develops and manufactures bioabsorbable polymeric scaffolds, films and related instrumentation for the repair and replacement of bone, soft tissue and articular cartilage. Its products are based on proprietary and patented technologies covered by U.S. and foreign patents. The PolyGraft(R) product and related scaffold formulations are protected under U.S. Patent Nos. 5,716,413, 6,511,511 and other patents pending.
The Company is focused on commercializing and further developing its platform technologies in arthroscopy and sports medicine. Additionally, OBI is actively forming strategic alliances with companies serving other areas of medicine such as spine, trauma, general orthopedics, and wound care to leverage its technologies into those markets.
CONTACT:
Media, Paul Nichols of Nexa Orthopedics, Inc. (619)997-0103, pnichols@nexaortho.com
Daniel Lee of OsteoBiologics, Inc. (210)690-2131, daniel.lee@obi.com
Web sites http://www.nexaortho.com and http://www.obi.com
Nexa Orthopedics, Inc.
CONTACT: Media, Paul Nichols of Nexa Orthopedics, Inc. +1-619-997-0103,pnichols@nexaortho.com; or Daniel Lee of OsteoBiologics, Inc.,+1-210-690-2131, daniel.lee@obi.com